

Subject Index

- 22q11 78, 83, 190, 191, 216
- adolescence 188, 219, 227
cognitive decline in 229–233, 277–279
early 218, 233, 277–279
late 2, 14, 102, 104, 108, 186, 218, 233
- affective dysregulation 52, 143, 204
- agranulocytosis, clozapine-induced 104, 293
- altered sense of self 6, 10, 13, 87
- Alzheimer's disease 29, 36, 37, 55, 148
OE technology 177, 178
- amygdala 72, 108, 132, 161
- anhedonia 27, 53, 60, 86
- animal models 10–12, 83, 106, 147, 209, 217, 274, 275, 288
hypothesis-based 183–194, 219
limitations of 150, 168, 192
link to human cell models 179, 180
rodent 115, 117, 129, 133, 169, 180, 184, 185
role in novel therapeutics 192–194
validity in 184, 185, 189, 194, 210
- anterior cingulate cortex (ACC) 111, 120, 121, 130, 131, 152
- anti-inflammatory interventions 8, 106, 107, 124. *See also* omega-3 fatty acids
- antipsychotic medication 29, 41, 79, 82, 96, 110, 118, 265, 283, 293
effect on BOLD signal 121, 122
effect on prepulse inhibition 116
impact on cognition 73, 193, 232
- anxiety 15, 34, 61, 81, 83, 89, 97, 98, 138, 141, 142, 158, 159, 214, 242, 263
- aspirin 106, 123, 161
- assertive community treatment 13, 246, 247, 271
- assessment 15, 40, 71, 96, 147, 151, 153, 156, 157, 163
CARE program 116, 153
multidimensional 86–88
- personalized treatment 294, 295
virtual reality techniques 15, 290, 291
- associative thought disorder 27, 37
- at-risk mental state 8, 25, 34, 35, 108, 160, 161
secondary prevention 276, 277, 281, 282
- attachment 30, 61, 95, 149
- attention 17, 61, 63–66, 70–72, 120, 217, 244, 253
impaired 16, 37, 38, 157
selective 38, 39
- attractor states 21, 195, 198–200, 204, 220, 221
- autism 5, 19, 52, 83, 84, 94, 120, 129, 139, 193, 212, 213, 228
iPS cell characterization 172
- avolition 50–54, 58, 60, 77, 85, 87
- Avon Longitudinal Study of Parents and Children 154, 155
- AX continuous performance task 38, 39
- behavioral construct 6, 15, 49, 51, 56, 60, 61, 81, 86, 88
- biomarkers 55, 56, 59, 62, 79, 80, 102, 115, 121, 125, 142, 160, 287
abnormal gamma synchrony 88, 118, 221
mu rhythm suppression 119, 120
role of animal models 185, 191–194
- bipolar disorder 5, 6, 25, 29, 33, 35–37, 62, 83, 129, 151, 193, 228
cognitive function in 231–233, 278
OE technology 177, 178
predicting 146
risk factors 141, 142, 148
- Bleuler, Eugen 25, 27, 38, 52–54, 78, 228
- Bleuler, Manfred 94
- BOLD signal 121, 122
- bonding 149
- brain-derived neurotrophic factor (BDNF) 105, 123, 144

- brain function 3, 5, 6, 11, 20, 21, 63, 64,
70, 72, 131, 150
 computational models 196
- brain imaging 2, 71, 74, 79, 180, 294.
 See also neuroimaging
- CACNA1C 132, 205
- cancer 6, 84, 142
- candidate genes 61, 62, 103, 113, 131,
132, 150
- cannabis 4, 96, 104, 107, 140, 143, 145,
164
- CARE. *See* Cognitive Assessment and
 Risk Evaluation (CARE) program
- case formulation approach 254, 294
- catechol-O-methyl transferase (COMT)
96, 107, 112, 113, 115, 201, 205
- category fluency 66, 67, 231
- celecoxib 106
- cellular models. *See* human cellular
 models
- childhood abuse 4, 8, 19, 79, 141,
154–156, 279, 291
- chlorpromazine 55, 227, 232
- classification 55–58, 77–79, 227, 263,
264, 279, 282
 Kleist–Leonhardt 290
- clinical symptoms 77, 81, 86–88, 119,
214
 heterogeneity in 211
- clinical trials 13, 16, 63–67, 125, 288,
289
 barriers to 161, 194
- closed concept/construct 28–30, 36, 37,
41, 78, 85, 213, 277
- clozapine 55, 118, 123, 297
 agranulocytosis 104, 293
- CNTNAP2 213, 215
- CNTRICS. *See* Cognitive Neuroscience
 Treatment Research to Improve
 Cognition in Schizophrenia
- cognition 2, 16–18, 39, 40, 63, 96, 97,
109, 113, 142, 216, 228, 237, 294.
 See also social cognition
- impairments in 4, 17, 37–40, 58, 81,
85, 280, 282
- modeling 198–200
- Cognitive Assessment and Risk
 Evaluation (CARE) program 116,
153
- cognitive behavioral therapy (CBT) 8,
15, 82, 108, 109, 114, 122–125, 235,
237, 240–244, 253, 254, 257, 258,
271, 294–296, 303
- cognitive decline 79, 188, 189, 228–233,
278
 identifying 277–280
- cognitive–emotional impairment 63–73
- Cognitive Neuroscience Treatment
 Research to Improve Cognition in
 Schizophrenia (CNTRICS) 71, 115,
121
- cognitive remediation 16, 73, 74, 82, 96,
97, 109, 114, 122–125, 235, 237, 245,
251–253, 258, 282, 283, 286, 294
- computer-based 29, 69, 287
 defined 244
 target age 280
- comorbidity 35, 44–46, 79, 81, 143, 154,
264
- computational models 9, 12, 195–210,
220, 221
- computational neuroscience 195–197,
206, 275
- congenital blindness 19, 20
- connectivity. *See* neural connectivity
- construct validity 71, 115, 119, 184
- context processing 5, 39, 40, 202
- contingent reinforcement 235, 258
- continuous performance tests (CPT) 38,
39, 64, 66, 67, 71, 72
- copy number variants (CNVs) 83, 103,
129, 139, 140, 148, 190, 213, 218
- cortical disinhibition 110, 185–187,
191–194
- cortical morphogenesis 212
- cortisol 105, 147, 154
- COX-2 inhibitors 106, 123, 124
- cross-disciplinary translational research
127–136
- data mining 45, 86–89
- data sharing 22, 88, 155, 156
- deep brain stimulation 287, 295

- deficit schizophrenia 56, 58, 59, 61, 82, 87, 270
- deinstitutionalization 239, 261, 304
- delusions 2, 20, 29–31, 51–54, 58, 60, 77, 78, 82, 85, 97, 146, 228, 242
- dementia 6, 55, 113, 280
 Alzheimer's 29, 37, 148, 177, 178
 praecox 36, 52, 54, 77, 79, 93, 98, 227
- de novo* mutations 129, 130
- depression 34, 37, 60, 83, 85, 97, 98, 138, 141, 142, 157, 158, 161, 265, 288, 304
 MDD 58, 131, 132, 263
 treatment 105, 239, 242
- developmental models 56, 57, 163, 186–189
- diabetes 142, 145, 255, 283, 284
- diagnosis 2, 28, 31, 35, 49–62, 77–79, 81–84, 295
- Diagnostic Statistical Manual (DSM) 28, 51, 79, 82, 263, 282
 A criteria 51, 53, 54
 DSM-IV 30, 53, 54, 83
 DSM-5 46, 56, 58–61, 77
- diet 255, 282, 286
- dimensional psychopathology 290, 291
- direct cell conversion 174–176, 222
- DISC1 128, 180, 190, 213, 215, 218
- discrimination 4, 13, 130, 268, 302, 304
- disease entity 52–58, 78, 80, 81, 84
 defined 50
- disorganization 40, 54, 77, 81, 85
 social 20, 21
 thought 51–53, 58, 60, 85
- dopamine 6, 103, 107–111, 115–117, 121, 144, 147, 187, 206, 218, 219
 animal models 192
 antagonists 41, 54, 81
 dual-state theory 204
 dysfunction 189, 201
 hypothesis 13, 109, 124, 184, 192
- dorsolateral prefrontal cortex (DLPFC) 120, 150, 151, 160
- drug abuse. *See* substance abuse
- drug development 3, 10, 13, 65, 168, 275, 287, 288, 289
 me-too 54, 55
- drug screening 11, 169, 171, 189, 210
- DSM. *See* Diagnostic Statistical Manual
- dual-state theory of prefrontal dopamine function 204
- Dunedin birth cohort 154, 155, 229
- dysbindin 190
- early adolescence 218, 233
 cognitive decline in 277–279
- early adulthood 2, 14, 102, 188, 218, 233
- early intervention 63, 73, 105, 123, 158–161, 281, 291
- early psychosis 101–126
 neurocognition in 112–114
 treatment of 104–107
- eccentricity 30, 32
- EEG gamma synchrony 71, 72
- eicosapentaenoic acid (EPA) 111, 113
- electrophysiology 115–120
- emotion 53, 68, 87, 241, 255, 278. *See also* cognitive–emotional impairment, social cognition
 impaired 63, 70–73
 recognition 117, 120
 relevance to olfaction 178
- empathy, impaired 53
- employment 2, 14, 70, 281
 supported 235–237, 241, 242, 244, 247, 258, 271, 303, 304
- empowerment 238, 245, 268, 270, 296
- endophenotype 16, 17, 27, 42, 55, 132, 155, 185, 191, 192
- environmental models 189, 190
- environmental risk factors 101, 104, 150, 163, 190, 216, 217, 270, 274, 280, 291. *See also* urban environment
- poverty 8, 9, 98, 281
- Environmental Risk Longitudinal Twin Study 154, 155
- Epidemiological Catchment Area Study 263
- epidemiology 4, 8, 9, 97, 127, 129, 133, 139, 140, 151, 152, 155, 213
 genetic 25, 26, 36, 46, 83
- epigenetics 8, 101, 104–107, 137, 149, 291

- epilepsy 6, 11, 18, 83, 84, 139, 212, 213, 217
- equipotentiality 27, 44, 45
- ethnicity 105, 130, 140, 145, 156, 158, 163, 281
- etiology 2, 14, 18, 28, 50, 81, 84–86, 89, 209
 models for understanding 42–45
 role of animal models 194
 systemic view 284
 traditional view of 283, 284
- etiology–pathophysiology–symptoms (E–P–S) framework 211–214, 219, 220, 223
- event-related potentials (ERPs) 118, 147, 151
- evidence-based medicine 240, 268
- evidence-based treatment 13, 14, 271, 295, 297–299
 National Implementing Evidence-Based Practices Project 247, 248
- excitation–inhibition balance 184, 186, 188, 193, 212, 218, 219
- executive function 17, 63, 64, 66, 88, 120, 132, 244
- exercise. *See* physical activity
- externalizing 30–34, 37
- face validity 11, 184, 210
- family history 34, 79, 89, 94, 95, 103, 140, 146, 154
- family intervention 235, 236, 240, 241, 244, 247–249, 251, 253, 271, 294, 304
 training for 257, 258
- fault tree analysis 25, 43–46
- functional capacity 63, 70, 72, 124
- functional connectivity 19, 71, 132, 150, 151, 170. *See also* neural connectivity
- functional imaging 115–122
 fMRI 3, 4, 15, 70, 71, 130, 131, 150
- functional outcome 64, 72, 77, 95, 114, 238. *See also* outcome
 determinants of 69, 70, 96, 112, 227, 228, 232
 improving 124, 245, 283
- future research 6, 21, 33, 59, 71, 73, 81, 88, 114, 124, 134, 139, 152, 157, 163, 173, 179, 215, 251, 259, 275, 279
- GABA 5, 88, 110, 111, 119, 180, 184, 192, 202
- gamma synchrony 71, 72, 119, 220, 221
 abnormal 88, 118
- gene–environment interactions 10, 94, 98, 134, 143, 149, 151, 152, 170, 279
- generalized deficit 17, 25, 38–40
- genetic epidemiology 25, 26, 36, 46, 83
- genetic models 147, 173, 183, 190, 191, 288
- genetic risk 7, 34–37, 79, 83, 94, 97, 103, 140, 147, 150, 151, 155, 213, 217, 228, 229, 232, 274
- genetics 3, 6, 13, 77, 127, 137, 139, 140, 148–150, 155, 164
 imaging 131, 132, 150, 274
- genome-wide association (GWA) studies 103, 131, 132, 146, 151, 213
- genotype 96, 113, 216, 222, 293
- glutamate 109–111, 115, 116, 121, 124, 148, 180, 192
- goal setting 235, 254, 255, 258, 266, 283
- gray matter loss 108–112, 117, 119, 124, 125, 141, 146
- hallucinations 2, 20, 30, 50–54, 58, 60, 77, 78, 85, 204, 228, 242
- haloperidol 73, 122
- Head Start 280, 282
- health economics 2, 268, 269, 299, 300
- health policy 14, 79, 247, 248, 261, 268, 269, 292, 299, 303
- help-seeking behavior 261, 264–269, 276
- heritability 102, 131, 132, 217
- heterogeneity 3, 5–7, 11, 21, 33, 49, 51, 54, 69, 77–90, 102, 128, 130, 137, 139, 141, 142, 193, 211, 216, 273, 289, 294
 conceptual paradigms 84–88
 in iPS cells 170, 173
 reducing 56, 84, 88, 213

- hippocampus 108, 109, 111, 121, 123, 150, 151, 187, 189, 200, 218
neurogenesis 286
prefrontal connectivity 214, 216
- homeorhesis 284, 285
- human cellular models 12, 167–182, 209, 210, 221–223
defined 167
translation of 180, 181
- human olfactory neurons 176–179
- Huntington's disease 184
- hypoferremia 106
- hypokrisia 27
- hypothalamic-pituitary-adrenal (HPA) axis 9, 105, 130, 141, 147
dysregulation 108, 130
- hypoxia 104, 140, 190
- imaging genetics 131, 132, 150, 274
- immune activation 107, 186, 188, 189, 192
maternal 104, 106, 132, 133, 216
- impaired insight 53, 54, 81, 303
- implementation science 250, 251, 259, 297, 298
- independent living 70, 236, 243, 255, 258, 268, 283
- individualized treatment 102, 103, 125
- induced neuronal (iN) cells 167, 170, 174–176, 180, 181
- induced pluripotent stem (iPS) cells 167, 170–173, 175, 180, 181, 222, 274, 288
- information processing 198–200
- Integrated Psychological Therapy (IPT) 253
- intellectual ability 96–98, 129, 231
deterioration 69, 110, 227
low IQ 8, 228–231, 233, 278
- intellectual disability 83–85, 212, 213, 279
- interactive developmental systems model 56, 57
- interleukin-6 186, 214
- internalizing 30–34, 37
- International Classification of Diseases (ICD) 28, 51, 79
ICD-10 77, 83, 282
- International Schizophrenia Consortium (ISC) 146
- interventions 14, 15, 21, 61, 80
psychosocial 13, 79
school-based 9
- IQ. *See* intellectual ability
- Jaspers, Karl 53, 79
- ketamine 105, 115, 116, 119, 185
- ketoconazole 105
- Kraepelin, Emil 25, 27, 38, 52, 53, 77, 78, 81, 93, 98, 227, 228, 233
- labeling theory 302
- Langfeldt, Gabriel 52, 53
- late adolescence 2, 14, 102, 104, 108, 186, 218, 219, 233
- learning disabilities 19, 80, 85, 139
- life-crisis model 270, 303
- life expectancy 3, 79, 282, 285, 286
- lithium 109, 123, 124
- low intelligence (IQ) 8, 228–231, 233, 278
- LY404039 111
- major depression disorder (MDD) 58, 131, 132, 263
- mania 30, 32, 58, 60, 85
- maternal age 140
- maternal immune activation 104, 106, 132, 133, 189, 216
- MATRICES 64, 69, 71, 72, 113, 115
- medical model 51, 54, 298
- medication management 304
- Meehl, Paul 26–28, 35, 37, 42, 45
- melanocortin 293
- memantine 116, 118
- memory 17, 55, 63, 70, 157, 202, 244.
See also verbal memory, working memory
epigenetic 170, 173, 175

- mental disorder, defined 50
 mental health care
 access to service 262, 270
 cost-benefit ratio 268, 269, 300
 patient-therapist relationship 261, 267, 270, 296
 mental health policy. *See* health policy
 mental health professionals 270, 298
 training 235, 248, 249, 256–259, 299
 mental health promotion 281, 282, 286
 mental illness, defined 50
 mesolimbic dopaminergic system 130, 141
 metabolic syndrome 285, 291
 methionine 144
 methylazoxymethanol acetate (MAM) 187–189, 215
 migrant status 47, 104, 105, 130, 140, 164
 minocycline 106, 113, 124, 161
 mismatch negativity 117, 118
 modeling 10–12, 81, 186–189, 209–224, 217. *See also* computational models
 neonatal ventral hippocampal lesion (NVHL) model 187–189
 time course 218–220
 molindone 73
 mood disorders 81, 87, 131, 154, 159
 mortality 3, 282, 285, 286
 motivation 4, 6, 16, 61, 87, 217, 255, 283, 286
 relation to olfaction 178
 motivational interviewing 283, 296
 motor development 7, 98
 mu wave suppression 119, 120

 N-acetylcysteine 116, 118
 National Comorbidity Survey (NCS) 263
 National Implementing Evidence-Based Practices Project 247, 248
 negative symptoms 15, 51, 53, 54, 58, 77, 78, 81, 85, 287
 treating 82, 106, 111, 113, 117, 124, 160
 neonatal ventral hippocampal lesion 187–189, 215, 216

 neural connectivity 93, 98, 99, 108, 112, 121, 122, 125, 132, 150, 151, 170
 measure of 70, 71
 neural synchrony 71, 72, 88, 118, 119, 151, 191, 216, 218, 220, 221
 neural system dynamics 198–200
Neurexin 81, 84
 neurobiology 9, 133, 150–152
 neurocognition 111–113, 118, 124
 neurofeedback training 120
 neurogenesis 109, 124, 286
 neuroimaging 86, 115–122, 137, 150, 151, 154, 287, 289. *See also* brain imaging
 neuroinflammation 105, 106, 111
 neuroticism 132
 neurotoxicity 101, 111, 121, 124
 New York High-Risk Project 38
 nicotinic receptors 113, 118
 NMDA 186, 202, 214
 antagonists 111, 116, 117
 blockade 185
 receptor hypofunction 109, 111
 nondeficit schizophrenia 56, 58, 87
 nonspecificity 47, 137, 139, 142
 nosology 26, 36, 41, 46, 84
 defined 50
NR3C1 130
NRXN1 215
 nutrition 98, 104, 149, 157, 159, 160, 276, 280–282, 285

 obsessive compulsive disorder (OCD) 108, 124
 obstetric complications 104, 140, 141, 154
 olanzapine 73, 192
 olfactory epithelium (OE) 167, 170, 177, 180, 181
 biopsy 167, 176, 178, 222
 technology 179
 omega-3 fatty acids 8, 106, 107, 111, 113, 123, 124, 282
 open concept/construct 6, 18, 29, 30, 33, 36, 41, 47, 78, 79, 85, 210, 277
 optogenetics 198, 204, 288

- outcome 10, 42, 44, 56, 73, 74, 209–224, 270. *See also* functional outcome evaluation 235, 247, 254, 279, 290, 299
heterogeneity 63, 77, 138, 139, 268, 273, 289
predictors 39, 71, 228, 232, 235, 261, 267, 296
oxidative stress 106, 178, 179, 184, 186, 188, 192, 214
oxytocin 117, 120, 295
- pandysmaturation 7
paranoia 30, 82, 86
Parkinson's disease 29, 177, 178, 184
paternal age 79, 104, 129, 130, 140, 141
paternal antisocial personality traits 143, 144
pathogenesis 4, 137, 147, 209, 211, 212, 219, 223
pathophysiology 3, 6, 8, 12, 51, 64, 77, 81, 85, 86, 89, 209
patient. *See also* empowerment
help-seeking behavior 261, 264–269, 276
relationship to therapist 261, 267, 296
Patient Outcomes Research Team (PORT) 239, 271
peer support 13, 80
perception 17, 61, 63, 72, 157, 216
treatment effects on 111–122
perigenual cingulate cortex (pACC) 151, 161
personalized medicine 6, 21, 169, 254–256, 288, 292–295
defined 293
patient's perspective 296, 297
pharmacogenomics 103, 104
pharmacological models 185, 186
phase 2 clinical trials 288, 289
phencyclidine 115, 118, 119, 185
phenotypic convergence 12, 211, 212, 215, 221, 222
physical abuse 4, 8, 19, 140. *See also* childhood abuse
physical activity 99, 105, 125, 159, 255, 280, 282, 285, 286, 290
pleiotropy 83, 217, 218
pluripotent risk state 8, 10, 86, 89, 142, 158, 159, 163
polygenic risk scores 146
poor rapport 53, 54
population-based sampling 97, 129, 153–155, 161, 163
positive symptoms 58, 63, 79, 81, 82, 120, 161, 204, 282, 297
link with dopamine 109, 192
positron emission tomography (PET) 71, 121, 154, 181, 280
postmortem brain analysis 58, 168–170, 187, 215
posttraumatic stress disorder 15, 29, 41, 95, 141, 270
poverty 8, 9, 98, 281
practice-based medicine 256, 259
predictive validity 146, 184, 210
prefrontal cortex 108, 109, 120–122, 144, 151, 188, 200–204, 206, 215
cortical thickness 219
dorsolateral 120, 150, 151, 160
medial 110
prenatal factors 47, 79, 98, 106, 133, 138, 150, 159
prepulse inhibition (PPI) 11, 115–117, 151, 187, 189, 191, 214
prevention 8, 14, 62, 97–99, 143, 158–161, 273, 280–282
primary 60, 89, 99, 276–278
secondary 60, 61, 89, 276–278, 281, 282
tertiary 14, 277, 281
Problem-Oriented Medical Information Systems (PROMIS) 15, 294
problem solving 64, 68, 70, 112, 244, 304
protection 94, 97, 102, 107, 109, 114, 123, 125, 140
proton magnetic resonance spectroscopy (¹H-MRS) 109–111, 121
psychiatric rehabilitation. *See* psychosocial interventions
defined 236
psychomotor impairment 51, 53, 54, 58, 77, 85, 244

- psychopathology 26, 56, 58, 61, 62, 97, 99, 282, 290
 development of 34, 35
 dissociative 52, 78
 domains 49, 50, 53, 59
 meta-structure of 30–34
 psychopharmacology 55, 265, 295
 psychosis 33, 47, 52, 54, 82, 97, 139–141, 213, 233, 276
 cognitive behavioral therapy for 242, 243
 impact of cognitive decline 228–230, 277
 treatments for early 101–126
 watershed analogy 42–44
 psychosocial functioning 238, 243–245, 250, 253, 254, 276, 282, 283
 improvements in 241
 psychosocial interventions 3, 13, 14, 93, 96, 124, 125, 161, 235–260
 access to 246–251
 implementing 249–251
 personalizing 254–256
 training for 256–258
 psychotherapy 108, 134, 144, 256, 262, 264, 265
 public awareness 13, 265, 268–270, 301
 public health interventions 98, 145, 158, 159, 276, 280–282, 286

 quality of life 122, 266–268, 273, 276, 297, 302, 303

 reality distortion 52–54, 58, 78
 real-time biofeedback 15
 reasoning/problem solving 64, 68, 70
 recovery 237–246, 296
 new conceptualization 238, 254, 258, 275, 276
 recovery movement 238, 245, 258, 275, 276, 296
 rehabilitation 232, 236–239, 245, 246, 251, 252, 258, 283, 297
 vocational 241, 303
 reinforcement learning 87
 relapse prevention 238, 244, 245, 253
 reliability engineering 41–45

 remission 231, 235, 238, 258, 275, 276
 Research Domain Criteria (RdOC) 27, 46, 56, 60, 61, 86, 123, 291
 resilience 7–10, 62, 89, 93–100, 131, 134, 137, 149, 152, 154, 158
 defined 93–95, 140
 restricted affect 53, 54, 58, 60, 85
 Rett syndrome 168, 172
 reward processing 217, 219
 modeling 199
 reward system 286
 rheumatoid arthritis 19, 20
 risk 4, 7–10, 19, 36, 89, 102–107, 115, 116, 130, 134, 140, 286
 estimating 153–155
 factors 47, 55, 89, 94, 98, 101, 137–164, 228–231
 role of animal models 185, 194
 intervention 280, 282
 phenotype 150, 233
 prediction 103, 144–147, 158
 specificity 141–143
 risperidone 73
 rodent models 115, 117, 129, 133, 169, 180, 184, 185
 limitations of 168, 192

 sampling 152–157, 289
 schizoaffective disorder 35, 54
 schizophrenia
 classification 227, 263, 264, 279, 282
 clinical syndrome 49–51, 54, 55, 60
 cognitive disorder 227–234
 deficit 56–61, 82, 87, 270
 defined 81, 234, 285
 interactive developmental systems model 56, 57
 nondeficit 56, 58, 87
 schizophrenia construct 78–89
 defined 1, 5, 6, 18, 51, 63, 77
 models of 78
 schizotaxia 26, 27, 37, 42
 schizotypy 19, 26, 27, 35, 37, 42, 155
 Schneider, Kurt 52–54, 78
 school-based interventions 9, 14, 159, 163, 237, 276, 277

- school performance 70, 142, 159, 228–232, 278, 280, 291
- secondary prevention 60, 61, 89, 276–278, 281, 282
- selective attention 38, 39
- self-care 70, 243, 246, 255, 283, 294
- self-esteem 268, 296, 303
- self-management 237, 243, 244, 253, 255, 258, 286
training 235, 245
- self-report measures 28, 32–34, 73, 153
- self-stigma 252, 255, 270, 302, 303
- serotonin 103, 111, 115, 132
reuptake inhibitors (SSRI) 109, 118, 123, 124
- service delivery 161–163, 235, 247, 273, 285, 292, 297, 298
business model for 299
- sexual abuse 4, 8, 19, 143, 154
- SHANK 213, 215
- shared decision making 238, 245, 258, 275, 296–299
- shared research platforms 127, 134. *See also* data sharing
- single nucleotide polymorphisms (SNPs) 103, 104, 112, 115, 140
- social adversity 9, 94, 140–143, 158, 280
- social cognition 2, 64, 68, 71, 72, 85, 117–120, 237, 253, 296
- social defeat 4, 8, 9, 105, 157
- social-emotional processing 130, 152, 159
- social isolation 187, 204, 214, 255, 286, 302
- social learning theory 243, 254
- social skills training 124, 235, 237, 243–245, 252, 253, 257, 258, 295, 304, 305
- socioeconomic status 47, 130, 156–158, 161
- sociology 9, 127, 128, 157
- SRGAP2* gene 168
- staging 56, 59–62, 89
- stakeholders 266–268, 299, 300
- stealing effect 93–95
- stigma 13, 54, 80, 159, 242, 252, 255, 262, 268–270, 280, 281, 285, 301–303
- stress 4, 15, 104–108, 130, 131, 147, 151, 164, 169, 216, 217, 304
management 237, 241, 257
oxidative 178, 179, 184, 186, 188, 192, 214
periadolescent psychosocial 89
posttraumatic 15, 29, 41, 95, 141, 270
- striatum 200, 215, 218, 219
hyperdopaminergia 121
- substance abuse 8, 9, 34, 36, 47, 81, 104, 108, 141, 142, 146, 282, 283. *See also* drug abuse
- suicide 270, 282, 286
- supported employment 235–237, 241–244, 247, 258, 271, 303, 304
effectiveness of 252–254
individual placement and support program 242
training for 257
- symptomatology 204, 209, 223
- synaptic connectivity 179, 200, 212, 213, 221
- synaptogenesis 109, 123
- syndrome 29, 30, 52
defined 50
- systemic disorders 172, 284, 285
- tardive dyskinesia 104, 291
- TEOSS trial 73
- tertiary prevention 14, 277, 281
- tetrahydrocannabinol (THC) 105, 107, 140
- thought disorder 20, 25, 26, 30–33, 40–42, 78, 87
associative 27, 37
heterogeneity of 45–47
- Timothy syndrome 172
- token economy 235, 240, 258, 271
- transcranial magnetic stimulation 15, 160, 287
- transduction methods 171, 173, 217
- translation
impact of heterogeneity on 5–7, 77
impediments to 80–84

- translation (continued)
 research 127–136, 275, 291, 292
- trauma exposure 142–145, 156, 164
- treatment 3, 12, 84, 261–272, 291, 293, 297. *See also* psychosocial interventions
- barriers 269–271
- costs 2, 14, 268, 269, 299, 300
- eclectic approach to 253, 282, 294
- effects on neurocognition 111–122
- evidence-based 13, 14, 271, 295–299
- goal setting 235, 254, 255, 258, 266
- improving outcomes 301–303
- outcome predictors 104, 123, 124, 235, 252, 261, 267, 279
- personalized 6, 102, 103, 125, 254–256, 292–296
- systemic view 284
- traditional view 283, 284
- tricyclic antidepressant 105
- validation 239, 240, 290
- treatment development 79, 93–99, 103, 122–124, 160, 205–207, 223, 239–241, 273, 287–294
- framework for 291–293
- investment in 299–301
- treatment outcome. *See* outcome
- tryptophan depletion 118
- twins 40, 94, 216, 229, 231, 278
- phenotypic heterogeneity 216
- unemployment 2, 80, 142, 255, 302
- urban environment 9, 15, 47, 98, 104, 105, 130, 131, 140, 143, 151, 152, 156, 158, 161, 163, 247, 280, 291
- validity 54, 88, 183, 185, 188, 189, 194
- construct 71, 115, 119, 184
- face 11, 184, 210
- predictive 146, 184, 210
- valine (Val) 144
- verbal learning 64–71
- disabilities 19, 85
- verbal memory 39, 112, 120–122, 231
- VIPR2* 84
- viral infection 4, 9, 89, 141, 171
- virtual reality tools 290, 291
- visual learning 64, 65, 68, 69
- visual processing 17–20, 39, 40, 82, 85
- contour recognition 217
- vitamin D 98, 190
- vitamin E 123
- vocational rehabilitation 124, 241, 242, 252, 303. *See also* supported employment
- volition 228
- watershed model of psychosis 42–44
- weight gain 73, 83, 104, 282–286, 293
- working memory 11, 17, 37, 39, 61, 64–66, 88, 97, 119–122, 150, 195, 200, 202, 204, 216–218
- zinc deficiency 106
- ZNF804A* 132, 151, 152